Clinical Trial Update: To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating adding Campath-1H (alemtuzumab) or ATG to fludarabine and low-dose busulfan conditioning for acute myeloid leukemia and myel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• ATG (anti-thymocyte globulin)
• Busulfex (busulfan)
• Campath-1H (alemtuzumab)
• Fludarabine (Fludarabine)

Snippet

Sponsor: Hadassah Medical Organization | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 3 | Status: WITHDRAWN